News

The company has posted net sales of $10.08 billion for the fourth quarter of 2008, an increase of 1%, compared to $9.93 billion reported for the fourth quarter

The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick Advance test, and represents a six-month increase in

Together with the hepatitis C virus (HCV) Respond-2 study, a pivotal Phase III study in patients who failed prior treatment that completed enrollment in November 2008, the company

In addition, there will be the elimination of approximately 410 CSO sales representative positions. In total, Sepracor sales positions will be reduced to approximately 1,325. These reductions, together

Excluding restructuring charges in both fiscal 2008 and 2009, third quarter fiscal 2009 adjusted operating income was $25 million, up 20%, and adjusted earnings per share were $0.63,

He earlier served as the president and chief executive officer (CEO) of Jostens, Inc., from 1994 to 2004 and as chairman from 1998 to 2004. Before joining Jostens,

The terms of the agreement includes an upfront payment, regulatory milestones and sales milestones. The total value of the upfront payment and milestones are $4.75 million. In addition,

The agreement calls for Medimetriks to receive a percentage of Perrigo’s net sales on the non-branded products, allowing Medimetriks to maximize its investment in its brands and maintain

In the study, an HIV-infected individual completed a 12 treatment study of the Aethlon Hemopurifier administered thrice weekly over the course of 30-days. The study was conducted at